human
respiratori
syncyti
viru
hrsv
lead
caus
worldwid
sever
acut
lower
respiratori
tract
infect
alri
mainli
bronchiol
pneumonia
infant
young
children
estim
new
case
alri
year
owe
hrsv
infect
million
children
younger
year
result
hospit
admiss
hrsv
infect
also
caus
death
year
young
children
occur
develop
countri
nair
et
al
shi
et
al
human
metapneumoviru
hmpv
also
viru
clinic
signific
van
den
hoogen
et
al
second
hrsv
caus
alri
young
children
edward
et
al
schuster
william
hrsv
hmpv
also
clinic
impact
elderli
adult
cardiopulmonari
diseas
impair
immun
system
hall
et
al
dowel
et
al
falsey
et
al
panda
et
al
hrsv
hmpv
recent
reclassifi
orthopneumoviru
metapneumoviru
genera
respect
newli
creat
pneumovirida
famili
detach
origin
paramyxovirida
famili
afonso
et
al
henc
hrsv
hmpv
share
clinic
biolog
featur
although
also
import
differ
exampl
number
gene
proteolyt
process
respect
fusion
f
glycoprotein
van
den
hoogen
et
al
hrsv
hmpv
genom
encod
three
glycoprotein
sh
g
f
insert
viral
membran
sh
small
hydrophob
protein
whose
function
still
unclear
incorpor
low
amount
viru
particl
bao
et
al
gan
et
al
g
heavili
glycosyl
highli
variabl
type
ii
glycoprotein
resembl
mucin
serv
viral
attach
protein
levin
et
al
thammawat
et
al
final
f
type
glycoprotein
fuse
viral
cell
membran
initi
stage
infecti
cycl
main
target
neutral
antibodi
recent
review
melero
ma
f
protein
synthes
precursor
requir
proteolyt
process
becom
function
hmpv
f
cleav
trypsinlik
proteas
outsid
cell
shirogan
et
al
hrsv
f
cleav
twice
insid
cell
two
polybas
site
recogn
furinlik
proteas
et
al
zimmer
et
al
begona
et
al
hrsv
f
hmpv
f
trimer
heterodim
f
protein
initi
fold
metast
prefus
conform
membran
fusion
f
glycoprotein
refold
seri
unstabl
intermedi
highli
stabl
postfus
conform
share
neutral
epitop
prefus
conform
lamb
et
al
mclellan
et
al
avail
vaccin
either
hrsv
hmpv
despit
greatli
need
wealth
data
support
conclus
neutral
antibodi
major
player
protect
hrsv
hmpv
infect
recent
review
melero
ma
major
antibodi
direct
f
glycoprotein
walsh
hruska
recent
shown
activ
present
human
sera
due
antibodi
specif
metast
prefus
f
conform
magro
et
al
ngwuta
et
al
search
new
hrsv
vaccin
reinvigor
recent
advanc
design
solubl
hrsv
f
protein
fold
either
prefus
mclellan
et
al
krarup
et
al
postfus
conform
mclellan
et
al
swanson
et
al
stabil
solubl
form
prefus
hrsv
f
shown
induc
higher
level
neutral
antibodi
solubl
postfus
hrsv
f
mice
cotton
rat
primat
mclellan
et
al
krarup
et
al
palomo
et
al
howev
postfus
f
advantag
highli
stabl
induc
sizeabl
level
neutral
antibodi
afford
protect
hrsv
share
certain
epitop
prefus
f
swanson
et
al
recent
structur
solubl
form
postfus
hmpv
f
determin
reveal
extens
similar
postfus
hrsv
f
despit
sequenc
ident
ma
et
al
addit
purifi
postfus
hmpv
f
protein
abl
elicit
high
titer
neutral
antibodi
mice
ma
et
al
monoclon
antibodi
capabl
neutral
hrsv
hmpv
report
corti
et
al
schuster
et
al
ma
et
al
howev
signific
detect
polyclon
antibodi
respons
elicit
solubl
postfus
form
either
hrsv
f
hmpv
f
ma
et
al
base
knowledg
gain
antigen
structur
two
protein
engin
seri
chimer
protein
certain
epitop
hrsv
f
graft
onto
hmpv
f
vice
versa
mice
inocul
purifi
chimera
elicit
antibodi
neutral
hrsv
hmpv
furthermor
case
test
immun
mice
chimer
protein
afford
protect
challeng
viru
use
graft
heterolog
antigen
site
passiv
transfer
mous
sera
also
reduc
significantli
lung
viru
titer
challeng
demonstr
promin
role
antibodi
protect
provid
chimer
f
protein
base
similar
hmpv
f
hrsv
f
antigen
site
ii
structur
ma
et
al
expect
certain
amino
acid
could
exchang
two
protein
without
disrupt
overal
local
fold
ma
et
al
inde
chimer
protein
fig
increas
number
hrsv
f
residu
replac
equival
postfus
hmpv
f
residu
express
high
level
therefor
initi
analyz
sinc
express
level
turn
former
protein
consid
much
helix
hmpv
f
site
ii
made
swap
seven
amino
acid
uniqu
protein
fig
b
addit
chimer
protein
incorpor
six
amino
acid
chang
hmpv
f
backbon
reproduc
almost
entir
amino
acid
sequenc
hrsv
f
site
ii
fig
b
readili
purifi
homogen
chromatographi
follow
gel
filtrat
show
characterist
cone
shape
postfus
hmpv
f
ma
et
al
examin
neg
stain
em
fig
test
bind
mab
lost
reactiv
hmpv
f
site
ii
mab
retain
reactiv
hmpv
f
site
mab
addit
gain
full
partial
reactiv
hrsv
f
site
ii
mab
motavizumab
mz
respect
fig
also
lost
reactiv
hmpv
f
site
mab
gain
full
reactiv
mz
also
fig
better
estim
affin
mz
chimer
protein
bind
respect
fab
fragment
postfus
hrsv
f
chimer
f
protein
assess
surfac
plasmon
reson
spr
fig
mz
fab
bound
chimera
k
similar
observ
postfus
hrsv
f
show
much
faster
k
protein
consequ
mz
affin
chimera
similar
postfus
hrsv
f
markedli
decreas
see
k
valu
bind
fab
detect
fig
although
bind
fab
slightli
faster
k
compar
postfus
hrsv
much
faster
k
reduc
affin
compar
postfus
hrsv
f
therefor
although
site
ii
particularli
protein
resembl
antigen
properti
site
hrsv
f
remain
distinguish
differ
chimer
protein
note
although
elisa
bind
mz
chimer
protein
follow
trend
fab
fragment
spr
signific
differ
could
perceiv
two
method
thu
wherea
bind
fab
neglig
spr
fig
substanti
bind
mab
observ
elisa
fig
similarli
although
bind
mab
mz
compar
postfus
hrsv
f
elisa
substanti
reduct
mz
fab
affin
chimer
protein
observ
spr
differ
like
due
higher
densiti
protein
bound
elisa
plate
spr
chip
bival
natur
antibodi
compar
monoval
fab
assess
immunogen
chimera
group
five
mice
inocul
twice
week
apart
im
purifi
protein
adjuv
cpg
inocul
regimen
use
postfus
hrsv
f
hmpv
f
control
three
week
last
immun
mice
bled
sera
test
elisa
antibodi
bind
postfus
form
either
hrsv
f
hmpv
f
fig
report
postfus
f
protein
induc
high
level
antibodi
bound
homolog
protein
fail
bind
bound
poorli
case
serum
mice
inocul
hmpv
f
test
hrsv
f
heterolog
protein
ma
et
al
contrast
antibodi
induc
chimera
show
substanti
bind
hmpv
f
also
hrsv
postfus
f
protein
fig
level
antibodi
bind
postfus
hrsv
f
even
higher
sera
mice
inocul
significantli
higher
p
sera
mice
inocul
hmpv
f
assess
whether
antibodi
bind
hrsv
f
observ
sera
mice
inocul
reflect
neutral
activ
viru
mous
sera
test
microneutr
assay
fig
sera
mice
inocul
hmpv
f
hrsv
f
protein
substanti
neutral
titer
homolog
viru
contrast
sera
mice
inocul
either
sizeabl
neutral
titer
hrsv
addit
neutral
hmpv
summari
antigen
characterist
chimera
reflect
reactiv
hrsv
f
site
mab
fig
correl
capac
induc
murin
antibodi
bound
hrsv
f
neutral
hrsv
infect
particularli
promin
case
note
howev
sera
quantit
correl
found
bind
neutral
titer
exampl
serum
mous
inocul
low
level
hrsv
antibodi
fig
neutral
hrsv
effici
fig
evalu
whether
induct
antibodi
chimer
protein
could
correl
protect
challeng
viru
group
eight
mice
immun
three
time
week
apart
either
adjuv
cpg
one
week
last
inject
mice
challeng
intranas
hrsv
strain
day
later
amount
viru
lung
extract
quantifi
plaqu
assay
parallel
three
group
five
mice
inocul
either
cpg
postfus
hrsv
f
hmpv
f
control
result
demonstr
signific
increas
antibodi
sera
mice
inocul
challeng
compar
postfus
hmpv
f
control
fig
although
spread
titer
individu
mice
inocul
averag
higher
neutral
titer
inocul
howev
group
individu
mous
titer
reach
valu
close
mice
inocul
postfus
hrsv
f
reduct
hrsv
replic
lung
inocul
mice
clearli
correl
note
induct
antibodi
neutral
hrsv
infect
fig
wherea
hrsv
reach
high
titer
lung
mice
inocul
either
cpg
hmpv
f
detect
viru
lung
mice
inocul
postfus
hrsv
f
two
mice
inocul
chimera
detect
viru
lung
two
mice
also
higher
titer
antibodi
sera
compar
fig
b
group
mice
inocul
protein
substanti
reduct
lung
viru
titer
compar
cpg
hmpv
f
control
remark
lung
mice
inocul
free
detect
viru
demonstr
efficaci
vaccin
protect
hrsv
infect
substanti
relev
antibodi
protect
mice
inocul
chimera
sera
group
mice
fig
pool
togeth
passiv
transfer
ip
new
mice
challeng
follow
day
amount
viru
fig
five
day
challeng
amount
viru
lung
extract
quantifi
plaqu
assay
result
fig
demonstr
viru
replic
high
titer
mice
receiv
sera
previous
inocul
either
cpg
hmpv
f
contrast
viru
detect
lung
mice
receiv
sera
mice
previous
inocul
hrsv
f
importantli
viru
titer
significantli
reduc
mice
receiv
sera
previous
inocul
particularli
ten
time
less
viru
found
lung
control
fig
worth
note
though
protect
afford
passiv
sera
mice
previous
inocul
reach
level
protect
provid
sera
mice
previous
inocul
hrsv
f
recent
demonstr
neutral
antibodi
human
sera
direct
prefus
form
hrsv
f
magro
et
al
ngwuta
et
al
site
mab
potent
neutral
antibodi
mclellan
et
al
mclellan
reason
test
possibl
extend
chimera
approach
conform
antigen
site
chimer
protein
fig
produc
protein
deriv
solubl
hrsv
f
stabil
prefus
conform
previous
report
mclellan
et
al
although
express
moder
level
fail
react
hmpv
f
site
iv
mab
thu
discontinu
studi
protein
five
amino
acid
antigen
site
iv
swap
correspond
residu
hmpv
f
fig
b
six
amino
acid
chang
introduc
chimera
make
purifi
homogen
characterist
globular
shape
prefus
hrsv
f
seen
em
fig
antigen
properti
protein
assess
elisa
mab
specif
hrsv
f
hmpv
f
protein
show
reduc
reactiv
mab
specif
hrsv
f
site
iv
gain
reactiv
mab
specif
site
iv
hmpv
f
fig
similarli
show
complet
loss
mab
bind
gain
increas
reactiv
mab
reactiv
although
much
reduc
mab
hrsv
f
hmpv
f
site
iv
ma
et
al
react
chimer
protein
fig
demonstr
retain
prefus
characterist
hrsv
f
backbon
reactiv
antibodi
determin
fig
retain
reactiv
three
mab
recogn
epitop
site
hrsv
f
mclellan
et
al
two
chimer
protein
also
react
two
mab
specif
recent
identifi
prefus
hrsv
f
antigen
site
v
gilman
et
al
contrast
fail
react
three
mab
recogn
motif
characterist
postfus
hrsv
f
rodriguez
et
al
use
immun
group
five
mice
two
dose
mix
cpg
assess
capac
induc
antibodi
elisa
bind
result
reveal
essenti
sera
mice
inocul
prefus
hrsv
f
postfus
hmpv
f
howev
substanti
increas
hmpv
f
bind
note
sera
mice
inocul
particularli
comparison
sera
mice
inocul
prefus
hrsv
f
fig
substanti
increas
hmpv
neutral
also
note
sera
mice
inocul
especi
compar
hrsv
f
control
fig
note
immun
mice
either
prefus
hrsv
f
postfus
hmpv
f
induc
signific
report
ma
et
al
despit
report
mab
like
ma
et
al
schuster
et
al
concept
univers
vaccin
nabel
fauci
recent
attract
much
attent
case
influenza
viru
kanekiyo
et
al
krammer
pales
yassin
et
al
human
immunodefici
viru
hiv
kwong
et
al
univers
vaccin
sought
overcom
strain
variabl
singl
immunogen
design
reorient
antibodi
respons
toward
rel
conserv
antigen
region
would
protect
infect
highli
diverg
antigen
variant
case
aim
develop
vaccin
relat
virus
famili
flavivirida
zika
dengu
virus
et
al
beyond
virus
univers
vaccin
also
design
neisseria
meningitidi
chimer
variant
factor
h
bind
protein
incorpor
epitop
highli
diverg
bacteri
strain
scarselli
et
al
studi
produc
chimer
protein
hrsv
f
hmpv
f
togeth
two
virus
repres
major
global
burden
alri
young
children
sinc
palivizumab
pz
human
neutral
murin
mab
studi
group
current
use
prophylact
treatment
infant
recogn
epitop
hrsv
f
antigen
site
ii
site
receiv
much
attent
hrsv
vaccin
field
structur
hrsv
f
site
ii
motif
toiron
et
al
conserv
prefus
postfus
conform
f
protein
thu
hrsv
f
site
ii
graft
onto
differ
protein
scaffold
focu
antibodi
respons
elicit
unnatur
antigen
site
hrsv
f
recogn
neutral
antibodi
mclellan
et
al
correia
et
al
luo
et
al
result
obtain
far
limit
success
sinc
antibodi
induc
mice
neutral
despit
abl
bind
hrsv
f
one
case
site
ii
graft
onto
immunoglobulin
scaffold
result
immunogen
induc
antibodi
mice
neutral
hrsv
vitro
although
rel
low
effici
luo
et
al
anoth
case
site
ii
scaffold
induc
antibodi
macaqu
mice
repeat
dose
correia
et
al
recent
solv
structur
hmpv
f
postfus
conform
reveal
high
level
similar
hrsv
f
particularli
antigen
site
ii
hypothes
exchang
amino
acid
two
protein
site
allow
proper
fold
express
chimer
molecul
inde
protein
display
em
characterist
cone
shape
postfus
hmpv
f
use
backbon
chimera
fig
addit
elisa
chimera
show
antigen
characterist
hrsv
f
site
ii
fig
fact
show
affin
mz
similar
hrsv
f
although
reduc
affin
mab
nevertheless
abl
elicit
mice
signific
antibodi
respons
hrsv
f
fig
addit
mice
immun
three
dose
fulli
protect
hrsv
challeng
although
two
mice
inocul
protect
hrsv
mice
one
higher
neutral
titer
protect
afford
chimer
protein
experi
fig
ascrib
exclus
antibodi
relev
antibodi
protect
substanti
result
adopt
transfer
experi
fig
sinc
studi
alreadi
demonstr
capac
postfus
hmpv
f
induc
protect
immun
respons
cotton
rat
cseke
et
al
hamster
herfst
et
al
mice
aert
et
al
macaqu
herfst
et
al
chimer
protein
could
advantag
epitop
scaffold
approach
would
confer
protect
simultan
one
viru
possibl
howev
need
test
directli
perhap
permiss
anim
model
cotton
rat
protect
upper
lower
respiratori
tract
hrsv
hmpv
could
assess
addit
primat
may
decis
model
test
optim
chimer
f
candid
work
perform
wen
et
al
report
singl
chimer
hmpv
f
protein
incorpor
certain
site
ii
amino
acid
hrsv
f
contrast
result
report
two
high
dose
fail
induc
antibodi
mice
one
five
mice
immun
elicit
antibodi
bound
faintli
hrsv
f
whether
differ
amino
acid
substitut
f
protein
differ
immun
protocol
account
discrep
result
report
us
wen
et
al
requir
investig
sinc
major
neutral
antibodi
hrsv
human
recogn
epitop
specif
prefus
f
magro
et
al
ngwuta
et
al
gilman
et
al
import
test
feasibl
conform
graft
hmpv
antigen
site
inde
show
characterist
prefus
hrsv
f
em
fig
reactiv
mab
fig
time
gain
reactiv
least
partial
mab
specif
hmpv
site
iv
protein
elicit
mice
polyclon
antibodi
respons
bound
hmpv
f
neutral
viru
chimer
protein
approach
describ
undoubtedli
requir
optim
graft
antigen
site
like
specif
prefus
hrsv
f
deserv
test
yield
certain
chimer
protein
shown
fig
turn
extrem
low
sens
worth
note
graft
hrsv
site
ii
yield
protein
could
express
purifi
incorpor
hmpv
f
site
ii
either
postfus
prefus
hrsv
f
ablat
express
match
chimer
protein
fig
thu
fine
tune
chang
introduc
chimer
protein
may
critic
express
immunogen
use
express
system
incorpor
chimer
protein
viral
vector
liang
et
al
viru
particl
mcginn
et
al
altern
improv
product
andor
immunogen
chimer
f
protein
nonetheless
result
present
repres
proof
principl
design
chimer
protein
may
use
singl
immunogen
induc
immun
respons
import
pneumovirida
member
hrsv
hmpv
follow
blasco
moss
plasmid
encod
solubl
form
either
hrsv
f
hmpv
f
protein
use
studi
hrsv
f
f
plasmid
encod
ectodomain
hrsv
f
residu
long
strain
stabil
prefus
conform
incorpor
mutat
describ
mclellan
et
al
mclellan
et
al
protein
includ
addit
intraprotom
disulfid
bridg
two
substitut
palomo
et
al
hrsv
f
f
plasmid
encod
residu
hrsv
f
ectodomain
long
strain
delet
fusion
peptid
residu
avoid
aggreg
mclellan
et
al
palomo
et
al
hmpv
f
f
plasmid
encod
residu
hmpv
f
ectodomain
natur
cleavag
site
substitut
polybas
furin
site
first
nine
amino
acid
fusion
peptid
residu
delet
ma
et
al
plasmid
encod
chimera
fig
obtain
mutagenesi
correspond
plasmid
use
phusion
mutagenesi
kit
thermo
fisher
scientif
design
primer
recommend
manufactur
sequenc
primer
obtain
author
upon
request
case
foldon
trimer
domain
meier
et
al
ad
f
protein
ectodomain
flank
upstream
tev
proteas
site
downstream
factor
xa
proteas
site
differ
plasmid
test
transient
express
chimer
protein
follow
monolay
cell
grow
dmem
supplement
fetal
calf
serum
infect
vaccinia
viru
vv
bfur
vey
et
al
moi
pfucel
follow
transfect
plasmid
mix
lipofectamin
invitrogen
hour
later
supernat
test
presenc
chimer
protein
elisa
antibodi
indic
figur
legend
product
vaccinia
viru
recombin
encod
chimer
protein
obtain
method
blasco
moss
base
recombin
plasmid
vaccinia
strain
lack
gene
encod
henc
defici
plaqu
format
standard
condit
plasmid
carri
complet
copi
gene
thu
via
homolog
recombin
restor
function
protein
produc
cell
infect
match
vaccinia
viru
purifi
cultur
supernat
use
column
follow
gel
filtrat
hiload
superdex
pg
column
describ
ma
et
al
mab
specif
either
hrsv
f
hmpv
f
indic
referenc
figur
legend
motavizumab
potent
deriv
palivizumab
robbi
et
al
produc
cell
transfect
plasmid
dna
encod
antibodi
heavi
light
chain
purifi
use
protein
fab
fragment
gener
papain
digest
mass
ratio
h
follow
passag
protein
remov
fc
fragment
antibodi
et
al
produc
grow
hybridoma
cell
rpmi
medium
supplement
fetal
calf
serum
antibodi
purifi
cultur
supernat
fab
fragment
produc
describ
assay
run
biacor
instrument
mab
coval
coupl
sampl
refer
cell
chip
respons
unit
ru
approxim
ru
protein
indic
figur
legend
bound
mab
fab
fragment
differ
protein
concentr
nm
inject
bind
data
fit
langmuir
bind
model
calcul
kinet
paramet
anim
studi
perform
regul
spanish
european
legisl
concern
vivisect
use
genet
modifi
organ
protocol
approv
de
de
la
del
bienestar
anim
instituto
de
salud
carlo
iii
cba
pa
specif
femal
balbc
mice
obtain
envigo
rm
spain
anim
ventil
rack
dark
schedul
ambient
temperatur
food
water
avail
ad
libitum
group
size
estim
use
previou
publish
data
ma
et
al
random
use
group
blind
procedur
use
experi
baselin
antibodi
igg
hrsv
hmpv
postfus
detect
limit
group
mice
inocul
im
bilater
quadricep
muscl
indic
amount
protein
see
figur
legend
pb
mix
equal
volum
cpg
magic
mous
adjuv
creativ
diagnost
number
dose
week
interv
indic
figur
legend
week
last
dose
mice
bled
submandibular
vein
obtain
serum
sampl
challeng
studi
mice
inocul
pfu
pb
strain
hrsv
purifi
supernat
cell
ultracentrifug
min
discontinu
sucros
gradient
sucros
five
day
later
mice
euthan
lung
remov
extract
made
ml
dulbecco
medium
fetal
calf
serum
hrsv
titer
lung
extract
determin
plaqu
assay
cell
et
al
test
mab
reactiv
ng
purifi
mab
pb
use
coat
microtit
plate
bind
block
bovin
serum
albumin
pb
serial
dilut
differ
protein
ad
well
h
room
temperatur
follow
excess
mab
mca
substrat
opd
ge
healthcar
extens
wash
water
done
step
optic
densiti
read
nm
test
mous
serum
reactiv
microtit
plate
coat
ngwell
purifi
protein
mm
ph
mm
nacl
bind
block
serial
dilut
sera
block
solut
ad
bound
antibodi
detect
goat
ig
opd
sera
test
bind
postfus
f
protein
foldon
motif
remov
elisa
antigen
pretreat
tev
proteas
remov
column
avoid
bind
antibodi
present
sera
ma
et
al
case
sera
test
bind
prefus
hrsv
f
antibodi
first
deplet
incub
bead
coat
protein
contain
foldon
domain
pallesen
et
al
recombin
virus
deriv
strain
hrsv
kind
gift
mark
peepl
columbu
oh
usa
sublineag
hmpv
kind
gift
bernadett
van
den
hoogen
ron
fouchier
rotterdam
netherland
mix
serial
dilut
mous
serum
ad
cultur
cell
grow
microtit
plate
hour
later
medium
replac
pb
gfp
fluoresc
measur
tecan
micropl
reader
valu
express
percent
viru
control
without
antibodi
purifi
protein
appli
grid
neg
stain
uranyl
format
describ
ma
et
al
imag
record
gatan
ccd
camera
jeol
microscop
oper
kv
anim
sampl
size
chosen
base
literatur
document
previou
result
obtain
similar
experi
ma
et
al
number
anim
use
studi
indic
figur
legend
inclus
exclus
criteria
use
studi
blind
investig
formal
random
result
express
individu
valu
mean
statist
signific
calcul
anova
follow
tukey
test
use
graphpad
prism
eo
jsm
jam
vm
design
studi
interpret
result
eo
oc
vm
perform
experi
im
provid
viru
supervis
challeng
experi
dl
mct
perform
electron
microscopi
jam
vm
supervis
studi
jsm
jam
wrote
manuscript
author
contribut
final
version
manuscript
author
declar
conflict
interest
